Literature DB >> 33388081

Onchocerciasis control in Ghana (1974-2016).

Nana-Kwadwo Biritwum1,2, Dziedzom K de Souza3, Odame Asiedu4, Benjamin Marfo4, Uche Veronica Amazigo5,6, John Owusu Gyapong7.   

Abstract

BACKGROUND: The control of onchocerciasis in Ghana started in 1974 under the auspices of the Onchocerciasis Control Programme (OCP). Between 1974 and 2002, a combination of approaches including vector control, mobile community ivermectin treatment, and community-directed treatment with ivermectin (CDTI) were employed. From 1997, CDTI became the main control strategy employed by the Ghana OCP (GOCP). This review was undertaken to assess the impact of the control interventions on onchocerciasis in Ghana between 1974 and 2016, since which time the focus has changed from control to elimination.
METHODS: In this paper, we review programme data from 1974 to 2016 to assess the impact of control activities on prevalence indicators of onchocerciasis. This review includes an evaluation of CDTI implementation, microfilaria (Mf) prevalence assessments and rapid epidemiological mapping of onchocerciasis results.
RESULTS: This review indicates that the control of onchocerciasis in Ghana has been very successful, with a significant decrease in the prevalence of infection from 69.13% [95% confidence interval) CI 60.24-78.01] in 1975 to 0.72% (95% CI 0.19-1.26) in 2015. Similarly, the mean community Mf load decreased from 14.48 MF/skin snip in 1975 to 0.07 MF/skin snip (95% CI 0.00-0.19) in 2015. Between 1997 and 2016, the therapeutic coverage increased from 58.50 to 83.80%, with nearly 100 million ivermectin tablets distributed.
CONCLUSIONS: Despite the significant reduction in the prevalence of onchocerciasis in Ghana, there are still communities with MF prevalence above 1%. As the focus of the GOCP has changed from the control of onchocerciasis to its elimination, both guidance and financial support are required to ensure that the latter goal is met.

Entities:  

Keywords:  Community-directed ivermectin treatment; Ghana; Ivermectin; Onchocerciasis control

Mesh:

Substances:

Year:  2021        PMID: 33388081      PMCID: PMC7778817          DOI: 10.1186/s13071-020-04507-2

Source DB:  PubMed          Journal:  Parasit Vectors        ISSN: 1756-3305            Impact factor:   3.876


  24 in total

1.  WHO programme gives hope to blind and partially sighted people in Africa.

Authors:  K Ahmad
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

2.  Onchocerciasis: The First Decade of Mectizantrade mark Treatment.

Authors:  S E Meredith; H B Dull
Journal:  Parasitol Today       Date:  1998-12

3.  Trachoma in northern Ghana: a need for further studies.

Authors:  Michael Ekuoba Gyasi; Agana Nsiire; Daniel Yayemain; Oscar Afari Debrah; Delali Asamani; John Gyapong; Winfried M K Amoaku
Journal:  Ophthalmic Epidemiol       Date:  2010-12       Impact factor: 1.648

Review 4.  The Mectizan Donation Programme--a 10-year report.

Authors:  H B Dull; S E Meredith
Journal:  Ann Trop Med Parasitol       Date:  1998-04

5.  WHO Expert Committee on Onchocerciasis. Third report.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1987

6.  Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa.

Authors:  Young Eun Kim; Jan H F Remme; Peter Steinmann; Wilma A Stolk; Jean-Baptiste Roungou; Fabrizio Tediosi
Journal:  PLoS Negl Trop Dis       Date:  2015-04-10

7.  Onchocerciasis transmission in Ghana: the human blood index of sibling species of the Simulium damnosum complex.

Authors:  Poppy H L Lamberton; Robert A Cheke; Martin Walker; Peter Winskill; J Lee Crainey; Daniel A Boakye; Mike Y Osei-Atweneboana; Iñaki Tirados; Michael D Wilson; Anthony Tetteh-Kumah; Sampson Otoo; Rory J Post; María-Gloria Basañez
Journal:  Parasit Vectors       Date:  2016-08-05       Impact factor: 3.876

Review 8.  Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators.

Authors:  Nana-Kwadwo Biritwum; Dziedzom K de Souza; Benjamin Marfo; Samuel Odoom; Bright Alomatu; Odame Asiedu; Abednego Yeboah; Tei E Hervie; Ernest O Mensah; Paul Yikpotey; Joseph B Koroma; David Molyneux; Moses J Bockarie; John O Gyapong
Journal:  PLoS Negl Trop Dis       Date:  2017-03-23

9.  Onchocerciasis Control: Vision for the Future from a Ghanian perspective.

Authors:  Mark J Taylor; Kwablah Awadzi; María-Gloria Basáñez; Nana Biritwum; Daniel Boakye; Boakye Boatin; Moses Bockarie; Thomas S Churcher; Alex Debrah; Geoffrey Edwards; Achim Hoerauf; Sabine Mand; Graham Matthews; Mike Osei-Atweneboana; Roger K Prichard; Samuel Wanji; Ohene Adjei
Journal:  Parasit Vectors       Date:  2009-01-21       Impact factor: 3.876

10.  Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?

Authors:  Kwadwo K Frempong; Martin Walker; Robert A Cheke; Edward Jenner Tetevi; Ernest Tawiah Gyan; Ebenezer O Owusu; Michael D Wilson; Daniel A Boakye; Mark J Taylor; Nana-Kwadwo Biritwum; Mike Osei-Atweneboana; María-Gloria Basáñez
Journal:  Clin Infect Dis       Date:  2016-03-21       Impact factor: 9.079

View more
  2 in total

1.  Demographic patterns of human antibody levels to Simulium damnosum s.l. saliva in onchocerciasis-endemic areas: An indicator of exposure to vector bites.

Authors:  Laura Willen; Philip Milton; Jonathan I D Hamley; Martin Walker; Mike Y Osei-Atweneboana; Petr Volf; Maria-Gloria Basáñez; Orin Courtenay
Journal:  PLoS Negl Trop Dis       Date:  2022-01-12

2.  Occurrence of Lymphatic Filariasis infection after 15 years of mass drug administration in two hotspot districts in the Upper East Region of Ghana.

Authors:  Derrick Adu Mensah; Linda Batsa Debrah; Peter Akosah Gyamfi; Abu Abudu Rahamani; Vera Serwaa Opoku; John Boateng; Prince Obeng; Jubin Osei-Mensah; Inge Kroidl; Ute Klarmann-Schulz; Achim Hoerauf; Alexander Yaw Debrah
Journal:  PLoS Negl Trop Dis       Date:  2022-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.